Trial Profile
A Multi-Institutional, Investigator-Initiated Study Investigating Cetuximab in Patients with Bladder Cancer
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 18 Jan 2016
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary)
- Indications Bladder cancer
- Focus Therapeutic Use
- 18 Jan 2016 New trial record
- 25 Nov 2008 The National Comprehensive Cancer Network (NCCN) was awarded a $US1.5 million grant from Bristol-Myers Squibb Company and ImClone Systems Incorporated to fund research of cetuximab in patients with bladder cancer, according to a NCCN media release.